Business Description
Oryzon Genomics is a Spanish clinical-stage pharmaceutical company focused on developing treatments that work by modifying gene activity, with a particular focus on blood cancers, brain tumors, and psychiatric conditions. Its two lead drug candidates are currently in Phase II trials ? one targeting certain cancers and another aimed at neurological and mental health disorders. The company also has earlier-stage programs working toward treatments for non-cancer diseases and conditions affecting the nervous system, including ALS and Charcot-Marie-Tooth disease. Founded in 2000 and headquartered near Barcelona, Oryzon works alongside academic and medical partners in both the United States and Spain to better understand and treat patients with specific genetic profiles.
